Khare et al. [9] were the first to observe that orally supplemented UDCA downregulated COX-2 expression in tumor colonocytes by reducing both deoxycholic acid-linked C/EPBbeta upregulation and COX-2 promoter activation. The gene discussed is PTGS2; the disease is neoplasm.